The art of financing and being financed in life sciences

Transcription

1 eithealth.eu Hyatt Regency Düsseldorf 7 th BIO.NRW Business Angel Congress The art of financing and being financed in life sciences March, 1 st 2018, Hyatt Regency, Speditionsstraße 19, Media Harbour, Düsseldorf #B_Angels18

2 11:30 Guided K21 Exhibition Tour (Meeting Point: K21 Ständehaus, Düsseldorf) Exhibitions K21 Artist s Rooms and Tomás Saraceno in orbit 12:30 Registration opens (at Hyatt Regency Düsseldorf) 13:00 Fingerfood 13:30 Welcome address Christoph Dammermann, State Secretary, Ministry of Economic Affairs, Innovation, Digitization and Energy of the State of North Rhine-Westphalia, Düsseldorf 13:40 Keynote Financing a company an art in multiple epoches Dr. Holger Zimmermann, CEO, Aicuris GmbH & Co. KG, Wuppertal and Board Member, BIO Deutschland e.v., Berlin Session 1: New approaches for investment facilities 14:00 Novel NRW program: Support of externally managed funds and support for founders Dr. Peter Güllmann, Head of Corporate Finance & Infrastructure Finance, NRW.BANK, Düsseldorf 14:15 The chances for and of new funds: For whom is it meant and why is it interesting? Rainer Christine, Managing Partner, Earlybird Health Tech Fund, Berlin/Munich Gonçalo Rebelo de Andrade, Hovione Capital, Lisbon 14:35 Crowdfunding an easy way for digital cross border financing? Dr. Patrick Pfeffer, CEO, aescuvest GmbH, Frankfurt am Main 14:45 EIT Health next step financing and why it is important to connect European innovation eco-systems Jan-Philipp Beck, CEO, EIT Health e.v., Munich

3 15:00 Coffee Break Session 2: Best practice examples for seed- and follow up-investments: How to match the needs? 15:20 Example 1: NUMAFERM GmbH first financing round Dr. Christian Schwarz, CEO, Philipp Bürling, CFO, NUMAFERM GmbH, Düsseldorf 15:35 The view of a Business Angel: Money is nice but not everything Prof. Dr. Detlev Riesner, Private Investor, BIO.NRW Business Angel Circle, Düsseldorf 15:45 The impact of corporate VC funds Dr. Jens Busse, Investment Manager, Evonik Venture Capital, Essen 15:55 The impact of the High-Tech Gründerfonds Dr. Michael Brandkamp, CEO, High-Tech Gründerfonds GmbH, Bonn 16:05 Example 2: Miracor Medical Systems GmbH (Miracor Austria) and Miracor Medical SA (Miracor Medical) how to initiate and manage follow-up financing Olivier Delporte, CEO, Miracor Medical S.A., Awans, Belgium 16:20 Follow up-investments: playing field for VCs such as Coparion and Earlybird? Dr. Sebastian Pünzeler, Venture Capital Investment Manager, Coparion GmbH & Co. KG, Köln Rainer Christine, Managing Partner, Earlybird Health Tech, Berlin/Munich 16:40 Discussion Round Is there something like a targeted investment process? What does it look like? Dr. Michael Brandkamp, CEO, High-Tech Gründerfonds GmbH, Bonn

4 17:10 Coffee Break Prof. Dr. Gunther Hartmann, Institute for Chemical and Clinical Pharmacology, University Bonn Dr. Marcus Kostka, Director, Investment Manager of the Boehringer Ingelheim Venture Fund, Ingelheim Dr. Katharina Ladewig, Managing Director, EIT Health (Germany) & EIT Health (UK-Ireland) Prof. Dr. Detlev Riesner, Private Investor, BIO.NRW Business Angel Circle, Düsseldorf Session 3: Changing environment new opportunities and chances 17:30 British Capital before and after Brexit N.N. 17:45 China Opportunities Pitfalls in attracting and dealing with investors from China Peter Homberg, Partner, Dentons Europe LLP, Frankfurt am Main 18:00 Every day life experience with a chinese investor Dr. Albrecht Läufer, CEO, BluCon Biotech GmbH, Köln 18:15 General Discussion How much public money and funds are needed to induce sufficient private investments? Moderation: Dr. Bernward Garthoff, Chair of Cluster Biotechnology North Rhine-Westphalia, Düsseldorf Roland Oetker, Private Investor, ROI GmbH, Düsseldorf Prof. Dr. Detlev Riesner, Private Investor and BIO.NRW Business Angel Circle, Düsseldorf Dr. Aristotelis Nastos, Head of Life Sciences and Cleantech, NRW.BANK, Düsseldorf Daniel Beck, Investment Manager, European Investment Fund, Luxemburg Wolfgang Kintzel, COO, Ayoxxa GmbH, Köln 19:00 Networking Dinner

5 REGISTRATION 7 th BIO.NRW Business Angel Congress The art of financing and being financed in life sciences March 1 st 2018, Hyatt Regency, Media Harbour, Düsseldorf Registrations must be received in writing by letter, fax ( ), or (info@bioclustermanagement.de) Name, First Name Company or Organisation Phone Invoice Adress Company or Organisation Name, First Name Street Zip Code City Country Member of the I will attend I will attend the Förderverein the K21 exhibition Networking Dinner Biotechnologie NRW e.v. Registration Fee: 100, Euro plus VAT Members of the Förderverein Biotechnologie NRW e.v. get a 10% discount

6 Please register under: Guided K21 Exhibition Tour (Ständehaus) Please note that all attendees of the exhibition tour meet directly at the K21 Ständehaus (Ständehausstraße 1, Düsseldorf). After the tour a shuttle will be provided to the conference hotel. The K21 Ständehaus is a very special venue for young international artists and for the contemporary portions of the permanent collection. For detailed information about the exhibitions please visit the K21 homepage under: Maps & Directions to the conference hotel For detailed information please visit the Hyatt homepage under: An Event of Sponsors Media Sponsors Plattform Life Sciences